The Experts below are selected from a list of 10659 Experts worldwide ranked by ideXlab platform
Juan Sahuquillo - One of the best experts on this subject based on the ideXlab platform.
-
sulfonylurea receptor 1 transient receptor potential cation channel subfamily m member 4 and kir6 2 role in hemorrhagic progression of Contusion
Journal of Neurotrauma, 2019Co-Authors: Volodymyr Gerzanich, Svetlana Ivanova, Orest Tsymbalyuk, Jesse A Stokum, Seung Kyoon Woo, Amit Sharma, Fatih Akkentli, Ziyan Imran, Bizhan Aarabi, Juan SahuquilloAbstract:Abstract In severe traumatic brain injury (TBI), Contusions often are worsened by Contusion expansion or hemorrhagic progression of Contusion (HPC), which may double the original Contusion volume a...
-
sulfonylurea receptor 1 in humans with post traumatic brain Contusions
Journal of Neurotrauma, 2015Co-Authors: Tamara Martinezvalverde, Marc J. Simard, Marian Vidaljorge, Elena Martinezsaez, Lidia Castro, Fuat Arikan, Esteban Cordero, Andreea Rădoi, M A Poca, Juan SahuquilloAbstract:Abstract Post-traumatic brain Contusions (PTBCs) are traditionally considered primary injuries and can increase in size, generate perilesional edema, cause mass effect, induce neurological deterioration, and cause death. Most patients experience a progressive increase in periContusional edema, and nearly half, an increase in the hemorrhagic component itself. The underlying molecular pathophysiology of Contusion-induced brain edema and hemorrhagic progression remains poorly understood. The aim of this study was to investigate sulfonylurea 1/transient receptor potential melastatin 4 (SUR1-TRPM4) ion channel SUR1 expression in various cell types (neurons, astrocytes, endothelial cells, microglia, macrophages, and neutrophils) of human brain Contusions and whether SUR1 up-regulation was related to time postinjury. Double immunolabeling of SUR1 and cell-type– specific proteins was performed in 26 specimens from traumatic brain injury patients whose lesions were surgically evacuated. Three samples from limited ...
Volodymyr Gerzanich - One of the best experts on this subject based on the ideXlab platform.
-
sulfonylurea receptor 1 transient receptor potential cation channel subfamily m member 4 and kir6 2 role in hemorrhagic progression of Contusion
Journal of Neurotrauma, 2019Co-Authors: Volodymyr Gerzanich, Svetlana Ivanova, Orest Tsymbalyuk, Jesse A Stokum, Seung Kyoon Woo, Amit Sharma, Fatih Akkentli, Ziyan Imran, Bizhan Aarabi, Juan SahuquilloAbstract:Abstract In severe traumatic brain injury (TBI), Contusions often are worsened by Contusion expansion or hemorrhagic progression of Contusion (HPC), which may double the original Contusion volume a...
-
key role of sulfonylurea receptor 1 in progressive secondary hemorrhage after brain Contusion
Journal of Neurotrauma, 2009Co-Authors: Marc J. Simard, Svetlana Ivanova, Cigdem Tosun, Michael Kilbourne, Orest Tsymbalyuk, John Caridi, Kaspar Keledjian, Grant V Bochicchio, Volodymyr GerzanichAbstract:An important but poorly understood feature of traumatic brain injury (TBI) is the clinically serious problem of spatiotemporal progression ("blossoming") of a hemorrhagic Contusion, a phenomenon we term progressive secondary hemorrhage (PSH). Molecular mechanisms of PSH are unknown and efforts to reduce it by promoting coagulation have met with equivocal results. We hypothesized that PSH might be due to upregulation and activation of sulfonylurea receptor 1 (SUR1)-regulated NC(Ca-ATP) channels in capillary endothelial cells, predisposing to oncotic death of endothelial cells and catastrophic failure of capillary integrity. Anesthetized adult male rats underwent left parietal craniectomy for induction of a focal cortical Contusion. The regulatory subunit of the channel, SUR1, was prominently upregulated in capillaries of penumbral tissues surrounding the Contusion. In untreated rats, PSH was characterized by progressive enlargement of the Contusion deep into the site of cortical impact, including corpus callosum, hippocampus, and thalamus, by progressive accumulation of extravasated blood, with a doubling of the volume during the first 12 h after injury, and by capillary fragmentation in penumbral tissues. Block of SUR1 using low-dose (non-hypoglycemogenic) glibenclamide largely eliminated PSH and capillary fragmentation, and was associated with a significant reduction in the size of the necrotic lesion and in preservation of neurobehavioral function. Antisense oligodeoxynucleotide against SUR1, administered after injury, reduced both SUR1 expression and PSH, consistent with a requirement for transcriptional upregulation of SUR1. Our findings provide novel insights into molecular mechanisms responsible for PSH associated with hemorrhagic Contusions, and point to SUR1 as a potential therapeutic target in TBI.
Bita Zahabi - One of the best experts on this subject based on the ideXlab platform.
-
Effects of Oral Glibenclamide on Brain Contusion Volume and Functional Outcome of Patients with Moderate and Severe Traumatic Brain Injuries: A Randomized Double-Blind Placebo-Controlled Clinical Trial
World neurosurgery, 2017Co-Authors: Hosseinali Khalili, Nima Derakhshan, Amin Niakan, Fariborz Ghaffarpasand, Mohammad Salehi, Hamed Eshraghian, Alireza Shakibafard, Bita ZahabiAbstract:Objective This study investigated effects of oral glibenclamide on brain Contusion volume and functional outcome of patients with moderate and severe traumatic brain injuries. Methods A randomized clinical trial including 66 patients with moderate (Glasgow Coma Scale score 9–12) to severe (Glasgow Coma Scale score 5–8) traumatic brain injury and brain Contusions of n = 29) or placebo in the same dosage ( n = 23). Brain Contusion volumetry was performed on days 0, 3, and 7 using spiral thin-cut brain computed tomography scan (1-mm thickness). Outcome measures including modified Rankin Scale, Glasgow Outcome Scale, and Disability Rating Scale were evaluated 3 months after injury. Results There was no significant difference between the 2 study groups in baseline, day 3, and day 7 Contusion volumes. Patients receiving glibenclamide had a significantly lower expansion ratio from first to second volumetry ( P P = 0.003). There was no significant difference between the 2 groups regarding functional outcome measured by Glasgow Outcome Scale, modified Rankin Scale, and Disability Rating Scale. Conclusions Oral glibenclamide is associated with decreased Contusion expansion rate in patients with moderate and severe traumatic brain injuries sustaining cerebral Contusions.
Hosseinali Khalili - One of the best experts on this subject based on the ideXlab platform.
-
effects of atorvastatin on brain Contusion volume and functional outcome of patients with moderate and severe traumatic brain injury a randomized double blind placebo controlled clinical trial
Journal of Clinical Neuroscience, 2017Co-Authors: Gholam Reza Farzanegan, Hosseinali Khalili, Nima Derakhshan, Fariborz Ghaffarpasand, Shahram PaydarAbstract:Abstract The aim of the current study was to investigate the effects of atorvastatin on brain Contusion volume and functional outcome of patients with moderate and severe traumatic brain injury (TBI). The study was conducted as a randomized clinical trial during a 16-month period from May 2015 and August 2016 in a level I trauma center in Shiraz, Southern Iran. We included 65 patients with moderate (GCS: 9–13) to severe (GCS: 5–8) TBI who had brain Contusions of less than 30 cc volume. We excluded those who required surgical intervention. Patients were randomly assigned to receive daily 20 mg atorvastatin for 10 days (n = 21) or placebo in the same dosage (n = 23). The brain Contusion volumetry was performed on days 0, 3 and 7 utilizing spiral thin-cut brain CT-Scan (1-mm thickness). The outcome measured included modified Rankin scale (MRS), Glasgow Outcome Scale (GOS) and Disability rating Scale (DRS) which were all evaluated 3 months post-injury. There was no significant difference between two study group regarding the baseline, 3rd day and 7th day of the Contusion volume and the rate of Contusion expansion. However, functional outcome scales of GOS, MRS and DRS at 3-months post-injury were significantly better in atorvastatin arm of the study compared to placebo (p values of 0.043, 0.039 and 0.030 respectively). Even though atorvastatin was not found to be more effective than placebo in reducing Contusion expansion rate, it was associated with improved functional outcomes at 3-months following moderate to severe TBI.
-
Effects of Oral Glibenclamide on Brain Contusion Volume and Functional Outcome of Patients with Moderate and Severe Traumatic Brain Injuries: A Randomized Double-Blind Placebo-Controlled Clinical Trial
World neurosurgery, 2017Co-Authors: Hosseinali Khalili, Nima Derakhshan, Amin Niakan, Fariborz Ghaffarpasand, Mohammad Salehi, Hamed Eshraghian, Alireza Shakibafard, Bita ZahabiAbstract:Objective This study investigated effects of oral glibenclamide on brain Contusion volume and functional outcome of patients with moderate and severe traumatic brain injuries. Methods A randomized clinical trial including 66 patients with moderate (Glasgow Coma Scale score 9–12) to severe (Glasgow Coma Scale score 5–8) traumatic brain injury and brain Contusions of n = 29) or placebo in the same dosage ( n = 23). Brain Contusion volumetry was performed on days 0, 3, and 7 using spiral thin-cut brain computed tomography scan (1-mm thickness). Outcome measures including modified Rankin Scale, Glasgow Outcome Scale, and Disability Rating Scale were evaluated 3 months after injury. Results There was no significant difference between the 2 study groups in baseline, day 3, and day 7 Contusion volumes. Patients receiving glibenclamide had a significantly lower expansion ratio from first to second volumetry ( P P = 0.003). There was no significant difference between the 2 groups regarding functional outcome measured by Glasgow Outcome Scale, modified Rankin Scale, and Disability Rating Scale. Conclusions Oral glibenclamide is associated with decreased Contusion expansion rate in patients with moderate and severe traumatic brain injuries sustaining cerebral Contusions.
Nima Derakhshan - One of the best experts on this subject based on the ideXlab platform.
-
effects of atorvastatin on brain Contusion volume and functional outcome of patients with moderate and severe traumatic brain injury a randomized double blind placebo controlled clinical trial
Journal of Clinical Neuroscience, 2017Co-Authors: Gholam Reza Farzanegan, Hosseinali Khalili, Nima Derakhshan, Fariborz Ghaffarpasand, Shahram PaydarAbstract:Abstract The aim of the current study was to investigate the effects of atorvastatin on brain Contusion volume and functional outcome of patients with moderate and severe traumatic brain injury (TBI). The study was conducted as a randomized clinical trial during a 16-month period from May 2015 and August 2016 in a level I trauma center in Shiraz, Southern Iran. We included 65 patients with moderate (GCS: 9–13) to severe (GCS: 5–8) TBI who had brain Contusions of less than 30 cc volume. We excluded those who required surgical intervention. Patients were randomly assigned to receive daily 20 mg atorvastatin for 10 days (n = 21) or placebo in the same dosage (n = 23). The brain Contusion volumetry was performed on days 0, 3 and 7 utilizing spiral thin-cut brain CT-Scan (1-mm thickness). The outcome measured included modified Rankin scale (MRS), Glasgow Outcome Scale (GOS) and Disability rating Scale (DRS) which were all evaluated 3 months post-injury. There was no significant difference between two study group regarding the baseline, 3rd day and 7th day of the Contusion volume and the rate of Contusion expansion. However, functional outcome scales of GOS, MRS and DRS at 3-months post-injury were significantly better in atorvastatin arm of the study compared to placebo (p values of 0.043, 0.039 and 0.030 respectively). Even though atorvastatin was not found to be more effective than placebo in reducing Contusion expansion rate, it was associated with improved functional outcomes at 3-months following moderate to severe TBI.
-
Effects of Oral Glibenclamide on Brain Contusion Volume and Functional Outcome of Patients with Moderate and Severe Traumatic Brain Injuries: A Randomized Double-Blind Placebo-Controlled Clinical Trial
World neurosurgery, 2017Co-Authors: Hosseinali Khalili, Nima Derakhshan, Amin Niakan, Fariborz Ghaffarpasand, Mohammad Salehi, Hamed Eshraghian, Alireza Shakibafard, Bita ZahabiAbstract:Objective This study investigated effects of oral glibenclamide on brain Contusion volume and functional outcome of patients with moderate and severe traumatic brain injuries. Methods A randomized clinical trial including 66 patients with moderate (Glasgow Coma Scale score 9–12) to severe (Glasgow Coma Scale score 5–8) traumatic brain injury and brain Contusions of n = 29) or placebo in the same dosage ( n = 23). Brain Contusion volumetry was performed on days 0, 3, and 7 using spiral thin-cut brain computed tomography scan (1-mm thickness). Outcome measures including modified Rankin Scale, Glasgow Outcome Scale, and Disability Rating Scale were evaluated 3 months after injury. Results There was no significant difference between the 2 study groups in baseline, day 3, and day 7 Contusion volumes. Patients receiving glibenclamide had a significantly lower expansion ratio from first to second volumetry ( P P = 0.003). There was no significant difference between the 2 groups regarding functional outcome measured by Glasgow Outcome Scale, modified Rankin Scale, and Disability Rating Scale. Conclusions Oral glibenclamide is associated with decreased Contusion expansion rate in patients with moderate and severe traumatic brain injuries sustaining cerebral Contusions.